Intraoperative management of patients with heparin-induced thrombocytopenia.
For 11 patients with confirmed heparin-induced thrombocytopenia, we used reversible platelet inhibition with iloprost, a stable prostacyclin analogue, to permit safe heparin administration for cardiac (n = 9) or vascular (n = 2) operations. In vitro, iloprost (0.01 mumol/L) prevented both heparin-induced platelet aggregation and 14C-serotonin release in all patients. Therefore, intraoperatively, a continuous infusion of iloprost was started before administration of heparin and was continued until 15 minutes after administration of protamine. For cardiac patients, after heparin administration, the whole blood platelet count did not change (171,000 +/- 29,000/microL versus 174,000 +/- 29,000/microL, mean +/- standard error of the mean); no spontaneous platelet aggregation was observed, and plasma levels of the alpha-granule constituents platelet factor 4 and beta-thromboglobulin increased from 38 +/- 14 and 140 +/- 18 ng/mL to 591 +/- 135 and 235 +/- 48 ng/mL, respectively. Fibrinopeptide A levels actually decreased from 287 +/- 150 to 27 +/- 6 ng/mL. Furthermore, adenosine diphosphate-induced platelet activation was preserved, postoperative bleeding times were unchanged, and no heparin-related deaths occurred. Similar results were obtained in both vascular patients. We conclude that temporary platelet inhibition with iloprost now permits safe heparin administration in all patients with heparin-induced thrombocytopenia who require a cardiac or vascular operation.
Kappa
J R
JR
Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia.
Fisher
C A
CA
Todd
B
B
Stenach
N
N
Bell
P
P
Campbell
F
F
Ellison
N
N
Addonizio
V P
VP
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D001760:Bleeding Time; D011464:Epoprostenol / Q000097:blood / Q000627:therapeutic use*; D005344:Fibrinopeptide A / Q000378:metabolism; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D016285:Iloprost; D007432:Intraoperative Period; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000097:blood / Q000627:therapeutic use*; D010976:Platelet Count / Q000187:drug effects; D010978:Platelet Factor 4 / Q000032:analysis; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control*; D013929:Thromboxane B2 / Q000378:metabolism; D001620:beta-Thromboglobulin / Q000378:metabolism
D010975:Platelet Aggregation Inhibitors; D001620:beta-Thromboglobulin; D005344:Fibrinopeptide A; D010978:Platelet Factor 4; D013929:Thromboxane B2; D006493:Heparin; D011464:Epoprostenol; D016285:Iloprost; D001241:Aspirin